(Q73850570)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Oral absorption of the HIV protease inhibitors: a current update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Williams GC

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

211-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

cites work

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Human immunodeficiency virus protease inhibitors. From drug design to clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Preformulation studies of a novel HIV protease inhibitor, AG1343.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Targeting HIV-1 protease: a test of drug-design methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Single-Dose Pharmacokinetics of Indinavir and the Effect of Food.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Saquinavir. Clinical pharmacology and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

1 reference

7 January 2021

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

1 reference

7 January 2021

The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

The entry of antiviral and antiretroviral drugs into the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Indinavir in cerebrospinal fluid of HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

The barrier function of CYP3A4 and P-glycoprotein in the small bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

First-pass metabolism of midazolam by the human intestine.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Nelfinavir. A review of its therapeutic efficacy in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Overview: pharmacokinetic drug-drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Polypharmacy and the treatment of HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900027-7

7 January 2021

10.1016/S0169-409X(99)00027-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837775%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference